Sign In

Andrew Coop

SVP Head of Medical Affairs North America

Andrew Coop is the Senior Vice President and Head of Medical Affairs North America at Ipsen, a role he has held since April 2020. He is based in Cambridge, Massachusetts, and has extensive experience in the pharmaceutical industry, particularly in oncology.

Professional Background

  • Ipsen: Senior Vice President, Head of Medical Affairs North America (2020 - Present)
  • Pfizer: Vice President North America Medical, Oncology
  • AstraZeneca: Held various roles including Global Medicines Lead for Immuno-Oncology and Vice President of US Medical Affairs in Oncology.
  • Bristol-Myers Squibb: Served as Vice President and Executive Director in their oncology division.
  • Roche: Worked in multiple capacities related to global medical affairs in oncology.

Education

Andrew Coop earned his medical degree (MBChB Honours) and a Bachelor of Science in Molecular Biology from the University of Glasgow, where he studied from 1988 to 1995.

Additional Information

Before his corporate career, Coop worked as a clinical scientist and held various medical positions in hospitals. His background combines clinical expertise with leadership in medical affairs, focusing on oncology therapies. He has over 500 connections on LinkedIn, reflecting his extensive professional network within the industry.1

Highlights

Mar 30 · linkedin

With degrees in molecular biology and medicine, I have been involved in drug development for over 20 years.  It has always been science-led, personal, a pursuit of innovation and driven with a sense of urgency. These tenants are why I became a Rare Disease Renegade.

For more information and to support our mission please visit us at

https://lnkd.in/ed_SiC9Z

#RareDiseaseRenegades #DaretoRare

Within my lifetime, I have witnessed tremendous technological advancements. I was born in 1970, within a year of the first lunar landing, yet this incredible national achievement occurred only sixty-six years after the Wright Brothers conquered the air with their novel flight at Kitty Hawk, NC. The pace of this remarkable innovation leapfrogged within one lifetime, and we continue to witness this exponential progression of national advancement as it transitions to private sector opportunities for space tourism.

Throughout my career, I have witnessed the speed of innovation in oncology. In the past decades, the decoding of the human genome has allowed the creation of multiple innovative medicines in cancer, new ways to modulate the immune system, treating not only the symptoms of this devastating disease, but also the underlying causes. With that knowledge, urgency, renegade mindset, innovative trial design, private and public partnerships, deep translational science, groundbreaking novel treatments for both common and rare cancers have been developed and delivered to cancer patients. The pace of progress has been equally remarkable.

I have had the pleasure of working closely with Michelle Werner, and we have developed mutual admiration and friendship over the years working together and sharing our personal lives with each other. Her guidance has been instrumental for me as I navigate life and work. Michelle’s family received a devastating diagnosis of the scourge of a rare disease that has impacted her young family, and my devotion to her has been mandated to comfort, aid, and innovate with urgency to harness these innovated tools to combat rare diseases. These uncommon diseases, with underlying changes in genes, are devastating and often present in childhood with life-changing and life-shortening consequences. Up until now, the treatments have often aimed to target the symptoms, as opposed to the underlying genetic causes of these diseases which are often specific to each patient. What if we could apply the same urgency, same vision, same “moon shot” approach, as we have done in oncology and in space travel? What’s holding us back to dream big and do things differently? Do things faster, better?

Mar 23 · linkedin

I am humbled to announce that I am a newly appointed board member for the Rare Disease Renegades not-for-profit foundation.

This is deeply personal to me, having spent my entire professional career in life sciences. A friend and colleague of mine and her family have been impacted by the diagnosis of a rare disease, Duchenne Muscular Dystrophy. It’s personal, individual. It’s a devastating disease , and one where an innovative approach to research is needed.

We need your help. Become a Renegade. Get involved. Help us fund the research and cures these patients’ desperately need.

Please visit https://lnkd.in/evxeaRDQ for more information about the organization, events, and to donate to help make a difference. Thank you for becoming a Rare Disease Renegade.

Related Questions

What are Andrew Coop's main responsibilities at Ipsen?
How did Andrew Coop transition from Pfizer to Ipsen?
What significant projects has Andrew Coop led at AstraZeneca?
What is Andrew Coop's educational background?
How has Andrew Coop's career evolved in the pharmaceutical industry?
Andrew Coop
Andrew Coop, photo 1
Andrew Coop, photo 2
Add to my network

Location

United States